GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025

作者：Thorsten Simon, Theresa M. Thole, Sveva Castelli, Beate Timmermann, Danny Jazmati, Rudolf Schwarz, Jörg Fuchs, Steven Walter Warmann, Jochen Hubertus, Matthias C. Schmidt, Julian M.M. Rogasch, Friederike Körber, Christian Vokuhl, Jürgen Frank Schäfer, Johannes Hubertus Schulte, Hedwig E. Deubzer, Carolina Rosswog, Matthias Fischer, PETER J. LANG, Thorsten Langer, Kathy Astrahantseff, Holger N. Lode, Barbara Hero, Angelika Eggert · 发表于：Klinische Pädiatrie · 年份：2025 · DOI：10.1055/a-2556-4302 · 被引用次数：10 · 研究领域：Neuroblastoma Research and Treatments、Adrenal and Paraganglionic Tumors、Cancer, Hypoxia, and Metabolism

The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Many low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise disease characterization for each patient at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials.